Phase 4 N=22 Responses to Influenza Vaccine in Patients With Mitochondrial Disorders (MELAS)
MELAS Syndrome
Primary: Clinical Safety of TIV Vaccine — 4; 0; 0; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=32 A Dose-escalating Clinical Trial With KH176
MELAS · LHON · Leigh Syndrome
Primary: SAD: Change From Baseline in ECG Results by Timepoint: Corrected QT Interval According to Fridericia's Formula (QTcF) — 386.2; 395.0; 385.8; 399.3 msec
N/A N=110 Mitochondrial Stress, Brain Imaging, and Epigenetics
Mitochondrial Diseases
Primary: Average TSST-induced Elevation in Cortisol — 37.44; 33.86; 42.83; 45.42 ng*min/mL
Phase 2 N=27 Study of Idebenone in the Treatment of Mitochondrial Encephalopathy Lactic Acidosis & Stroke-like Episodes
MELAS Syndrome
Primary: Mean Change in Cerebral Lactate Concentration (as Measured by Magnetic Resonance Spectroscopy) — -0.09; 0.16; -0.49 IU
Phase 2 N=30 Safety, Tolerability, Efficacy of MTP-131 for Treatment of Mitochondrial Disease in Subjects From the MMPOWER Study
Primary Mitochondrial Disease
Primary: Distance Walked on the 6-minute Walk Test (6MWT) by Visit — 394.1; 378.2 meters
Phase 2 N=84 CHOCOlate MeLatonin for AdolescenT MigrainE
Migraine
Primary: Change in Mean Visual Analog Scale (VAS) Score — -2.3; -2.7 cm
Phase 1 N=6 Safety, Blood Levels and Effects of AUT00201 in Patients With MEAK
Myoclonus Epilepsies, Progressive
Primary: Number of Participants With Treatment-Related Adverse Events After Single Dose Treatment of AUT00201 Compared to Placebo — 5; 5 Participants
Phase 2 N=20 EPI-743 for Metabolism or Mitochondrial Disorders
Mitochondrial Disease · Neurology · Myopathy
Primary: Newcastle Paediatric Mitochondrial Disease Scale (NPMDS) Part I-III, Baseline — 23.9; 20.4 Units on a scale
Phase 2 N=40 The Use of a Mitochondrial Enhancement Treatment in Bipolar Disorder
Bipolar Depression
Primary: The 25-Item Hamilton Depression Rating Scale. — 23.3; 22.1; 17.5; 18.5 units on a scale
Phase 2 N=36 Safety, Tolerability, and Efficacy of MTP-131 for the Treatment of Mitochondrial Myopathy
Mitochondrial Myopathy
Primary: Change in Distance Walked (Meters) on the 6-minute Walk Test (6MWT) — 13.5; 36.5; 64.5; 20.4 meters
Phase 3 N=1,383 Evaluation of Pigmented Skin Lesions With MelaFind(R) System
Melanoma
Primary: Sensitivity and Specificity — 98.2; 9.5 Ratio * 100 — p=0.05
Phase 2 N=183 A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma
BRAF or NRAS Mutant Metastatic Melanoma
Primary: Percentage of Participants With Objective Response (OR) — 4.9; 14.5; 12.0 percentage of participants
N/A N=23 Interaction of Melatonin and MTNR1B Genotype on Glucose Control - Study 1
Glucose · Circadian Rhythm · Melatonin
Primary: Disposition Index — 1314.7; 984.5 index
Phase 1 N=12 TMI With HD Mel in ASCT for R/R Multiple Myeloma (BMT-03)
Multiple Myeloma, Relapsed · Multiple Myeloma, Refractory to Standard Treatment
Primary: Maximum Tolerated Dose (MTD) of Gy — NA Participants
N/A N=171 Medical Arm of the Interagency Registry for Mechanically Assisted Circulatory Support
Heart Failure · Systolic Heart Failure
Primary: Number of Heart Failure Participants Deceased at 24 Months — 43 Participants
Phase 2 N=39 Melatonin and the Metabolic Syndrome
Metabolic Syndrome
Primary: Metabolic Syndrome Components — -2.7; 4.7 mmHg — p=0.013
Phase 2 N=212 An Efficacy and Safety Study of 24 Week Treatment With Mavodelpar (REN001) in Primary Mitochondrial Myopathy Patients
Primary Mitochondrial Myopathy
Primary: Change in Distance Walked During a 12 Minute Walk Test — 26.75; 30.89 meters
N/A N=81 PatiEnt Neuropsychological outcomeS After laseR Ablation
Cognitive Change
Primary: Site-determined Cognitive Changes Per Domain — 49; 50.7; 32.9; 35.3 Score
Phase 2 N=24 Pharmacokinetic Study of Propylene Glycol-Free Melphalan HCl for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation
Multiple Myeloma
Primary: Cmax (Pharmacokinetics) — 7380 ng/ml
Phase 2 N=53 RTA 408 Capsules in Patients With Mitochondrial Myopathy - MOTOR
MItochondrial Myopathies
Primary: Change of Peak Workload (in Watts/kg) During Exercise Testing — 0.0090; 0.020; -0.0300; 0.1050 Watts/kg — p=0.7321
Phase 2 N=24 Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineered Lymphocytes
Melanoma · Skin Cancer
Primary: Clinical Tumor Regression. — 0; 0; 6; 0 Participants
Phase 2 N=51 Uproleselan (GMI-1271) for GI Toxicity Prophylaxis During Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation (Auto-HCT) for Multiple Myeloma (MM)
Multiple Myeloma
Primary: Change in Diarrhea as Assessed Per CTCAE v5.0 — 0.00; 0.13; 0.00; 0.13 CTCAE grade
Phase 2 N=43 Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation
Hematological Malignancy · Multiple Myeloma
Primary: Progression-free Survival (PFS) of Participants With Hematological Malignancies Undergoing Treatment. — 17 Participants
Phase 2 N=12 A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for Treatment of Leber's Hereditary Optic Neuropathy
Leber's Hereditary Optic Neuropathy
Primary: Double Masked Period: Incidence of Ocular TEAEs — 3; 8; 1; 3 eyes
Phase 2 N=14 Daylight-mediated Photodynamic Therapy of Actinic Keratoses:Comparing 0.2%HAL With 16%MAL
Actinic Keratoses
Primary: Histological Lesion Clearance — 38.5; 69.2 percentage of complete histological clea
N/A N=43 Study to Test Genetic Alterations Among Different Dermoscopic Types of Melanocytic Nevi.
Nevi
Primary: Frequency of BRAF Mutations Among Nevi — 6; 19 BRAF mutations
N/A N=36 Acute Effect of MMT Peel Powder on Glycemic Response, Satiety, and Food Intake in Adults at Risk for Type 2 Diabetes
At Risk of Type 2 Diabetes Mellitus
Primary: Blood Glucose Levels — 5.6; 5.7; 6.7; 7.7 mmol/L — p=<0.001
Phase 2 N=41 A Phase 2 Study to Evaluate the Impact of MTP-131 (Bendavia™) on Skeletal Muscle Function in Elderly
Skeletal Muscle Mitochondrial Dysfunction in the Elderly
Primary: Change From Baseline in ATPmax (Maximal ATP Synthetic Rate) — 0.17; 0.12; 0.09; 0.06 mM/sec
N/A N=18 Study of Laser Treatment of Melasma
Refractory Mixed Type Melasma
Primary: Melasma Area Severity Assessment (MASI) Score Change From Baseline to Follow Up — -5.6; 4.7 score on a scale
N/A N=25 A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis
Leukemia · Amyloidosis
Primary: Hematologic Response Rate — 2; 4; 8; 9 participants